The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

BACKGROUND: Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk of new-onset atrial fibrillation (AF) in T2DM p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Diabetol
Hlavní autoři: Ling, Ann Wan-Chin, Chan, Cze-Ci, Chen, Shao-Wei, Kao, Yi-Wei, Huang, Chien-Ying, Chan, Yi-Hsin, Chu, Pao-Hsien
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648323/
https://ncbi.nlm.nih.gov/pubmed/33158436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01162-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky